Efficacy of Janus kinase inhibitors in rheumatoid arthritis

被引：0
|
作者：
Camille Langbour
Jessica Rene
Philippe Goupille
Guillermo Carvajal Alegria
机构：
[1] CHRU de Tours,Service de Rhumatologie
[2] Université de Tours,undefined
来源：
Inflammation Research | 2023年 / 72卷
关键词：
Tofacitinib; Upadacitinib; Baricitinib; Filgotinib; Rheumatoid arthritis; Efficacy; Predictive factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1121 / 1132
页数：11
相关论文
共 50 条
  • [41] Janus kinase inhibitors: efficacy and safety
    Cohen, Stanley
    Reddy, Virginia
    CURRENT OPINION IN RHEUMATOLOGY, 2023, 35 (06) : 429 - 434
  • [42] Potential alleviation of bone mineral density loss with Janus kinase inhibitors in rheumatoid arthritis
    Chen, Yun-Wen
    Chen, Hsin-Hua
    Huang, Wen-Nan
    Chen, Jun-Peng
    Chen, Yi-Hsing
    Chen, Yi-Ming
    CLINICAL RHEUMATOLOGY, 2024, 43 (01) : 117 - 128
  • [43] Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
    Hall, Stephen
    Nash, Peter
    Rischmueller, Maureen
    Bossingham, David
    Bird, Paul
    Cook, Nicola
    Witcombe, David
    Soma, Koshika
    Kwok, Kenneth
    Thirunavukkarasu, Krishan
    RHEUMATOLOGY AND THERAPY, 2018, 5 (02) : 383 - 401
  • [44] Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis
    Venetsanopoulou, Aliki I.
    Voulgari, Paraskevi V.
    Drosos, Alexandros A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (05) : 485 - 493
  • [45] Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population
    Stephen Hall
    Peter Nash
    Maureen Rischmueller
    David Bossingham
    Paul Bird
    Nicola Cook
    David Witcombe
    Koshika Soma
    Kenneth Kwok
    Krishan Thirunavukkarasu
    Rheumatology and Therapy, 2018, 5 : 383 - 401
  • [46] Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors
    Koh, Jung Hee
    Lee, Bong-Woo
    Kim, Wan-Uk
    JOURNAL OF RHEUMATIC DISEASES, 2023, 30 (04): : 234 - 242
  • [47] Prediction of the intolerance or non-responder to Janus kinase inhibitors in patients with rheumatoid arthritis: a preliminary retrospective study with integrative cluster analysis
    Sugawara, M.
    Fujieda, Y.
    Noguchi, A.
    Tanimura, S.
    Shimizu, Y.
    Nakagawa, I.
    Yoshimura, M.
    Abe, N.
    Kono, M.
    Kato, M.
    Oku, K.
    Amengual, O.
    Yokota, I.
    Takahashi, H.
    Atsumi, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (09) : 1674 - 1680
  • [48] Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis
    Wei, Qige
    Wang, Hui
    Zhao, Jianglin
    Luo, Zhongping
    Wang, Chufeng
    Zhu, Chunmei
    Su, Na
    Zhang, Shengzhao
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [49] Evaluation of Real-World Evidence to Assess Effectiveness Outcomes of Janus Kinase Inhibitors for Rheumatoid Arthritis: A Systematic Review of US Studies
    Gandy, Chandler
    Bazzazzadehgan, Shadi
    Bruera, Sebastian
    Huang, Yinan
    DRUG HEALTHCARE AND PATIENT SAFETY, 2025, 17 : 25 - 49
  • [50] Tofacitinib: The First Janus Kinase (JAK) Inhibitor for the Treatment of Rheumatoid Arthritis
    Vyas, Deepti
    O'Dell, Kate M.
    Bandy, Jason L.
    Boyce, Eric G.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1524 - 1531
12345